CTOR – citius oncology, inc. (US:NASDAQ)
Stock Stats
News
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts [Yahoo! Finance]
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers [Yahoo! Finance]
Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR-T Therapy in High-Risk Diffuse Large B-Cell Lymphoma [Yahoo! Finance]
Form 8-K CITIUS ONCOLOGY, INC. For: Mar 10
Form 8-K CITIUS ONCOLOGY, INC. For: Mar 04
Form EFFECT CITIUS ONCOLOGY, INC.
Form POS AM CITIUS ONCOLOGY, INC.
Form SCHEDULE 13G/A CITIUS ONCOLOGY, INC. Filed by: ARMISTICE CAPITAL, LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.